Determinants for prediction of malignant potential by metalloproteinase:E-cadherin ratio in prostate core needle biopsy.
Identifieur interne : 002D36 ( Main/Exploration ); précédent : 002D35; suivant : 002D37Determinants for prediction of malignant potential by metalloproteinase:E-cadherin ratio in prostate core needle biopsy.
Auteurs : H. Ohmori [Japon] ; K. Fujii ; T. Sasahira ; R. Ukai ; M. Ikeda ; K. Kobayashi ; A. Maruyama ; H. KuniyasuSource :
- Pathobiology : journal of immunopathology, molecular and cellular biology [ 1015-2008 ] ; 2006.
Descripteurs français
- KwdFr :
- ARN messager (génétique), ARN messager (métabolisme), Cadhérines (génétique), Cadhérines (métabolisme), Humains, Marqueurs biologiques tumoraux (génétique), Marqueurs biologiques tumoraux (métabolisme), Matrix metalloproteinase 2 (génétique), Matrix metalloproteinase 2 (métabolisme), Matrix metalloproteinase 9 (génétique), Matrix metalloproteinase 9 (métabolisme), Mâle, Ponction-biopsie à l'aiguille, Pronostic, Régulation de l'expression des gènes tumoraux, Stade de la tumeur, Tumeurs de la prostate (anatomopathologie), Tumeurs de la prostate (diagnostic), Tumeurs de la prostate (métabolisme), Valeur prédictive des tests, Valeurs de référence, Évolution de la maladie.
- MESH :
- anatomopathologie : Tumeurs de la prostate.
- diagnostic : Tumeurs de la prostate.
- génétique : ARN messager, Cadhérines, Marqueurs biologiques tumoraux, Matrix metalloproteinase 2, Matrix metalloproteinase 9.
- métabolisme : ARN messager, Cadhérines, Marqueurs biologiques tumoraux, Matrix metalloproteinase 2, Matrix metalloproteinase 9, Tumeurs de la prostate.
- Humains, Mâle, Ponction-biopsie à l'aiguille, Pronostic, Régulation de l'expression des gènes tumoraux, Stade de la tumeur, Valeur prédictive des tests, Valeurs de référence, Évolution de la maladie.
English descriptors
- KwdEn :
- Biomarkers, Tumor (genetics), Biomarkers, Tumor (metabolism), Biopsy, Needle, Cadherins (genetics), Cadherins (metabolism), Disease Progression, Gene Expression Regulation, Neoplastic, Humans, Male, Matrix Metalloproteinase 2 (genetics), Matrix Metalloproteinase 2 (metabolism), Matrix Metalloproteinase 9 (genetics), Matrix Metalloproteinase 9 (metabolism), Neoplasm Staging, Predictive Value of Tests, Prognosis, Prostatic Neoplasms (diagnosis), Prostatic Neoplasms (metabolism), Prostatic Neoplasms (pathology), RNA, Messenger (genetics), RNA, Messenger (metabolism), Reference Values.
- MESH :
- chemical , genetics : Biomarkers, Tumor, Cadherins, Matrix Metalloproteinase 2, Matrix Metalloproteinase 9, RNA, Messenger.
- chemical , metabolism : Biomarkers, Tumor, Cadherins, Matrix Metalloproteinase 2, Matrix Metalloproteinase 9, RNA, Messenger.
- diagnosis : Prostatic Neoplasms.
- metabolism : Prostatic Neoplasms.
- pathology : Prostatic Neoplasms.
- Biopsy, Needle, Disease Progression, Gene Expression Regulation, Neoplastic, Humans, Male, Neoplasm Staging, Predictive Value of Tests, Prognosis, Reference Values.
Abstract
According to a good correlation between in situ hybridization-based metalloproteinase-2/9:E-cadherin ratio (MER) and the pathological stage of prostate cancer, we set the cutoff line of MER at 6.0 (MER>6) to distinguish between organ-confined (pT2) and advanced diseases (pT3a-b/N1). In this study, we looked at the factors affecting MER and leading to a misprediction of the pathological stage. We examined MER in 39 paired specimens of prostate core needle biopsy and prostatectomy from the same patient and compared these MERs. In 34 (87%) of 39 cases, the MER of biopsy was correlated with the final pathological stage (pT2 vs. pT3a-b/N1). MER ranges in pT3a-b/N1 cancer were significantly wider than those in pT2 cancer (p < 0.01). The number of MER>6 fields in Gleason score 8-9 cancer was larger than that in Gleason score 7 cancer (p < 0.0001). In 5 cases where there was a failure to distinguish pT2 from pT3a-b/N1, the misdiagnosis was significantly associated with a small number of biopsies (4 or 6 specimens; p = 0.0469), a small amount of tumor tissue in biopsy specimens (less than 5 mm; p = 0.0492), and a wide MER range (more than 5.0; high intratumoral heterogeneity; p = 0.0202). Considering these factors increases the usefulness of preoperative prediction of the final pathological stage by MER in prostate cancer.
DOI: 10.1159/000094494
PubMed: 16943690
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002225
- to stream PubMed, to step Curation: 002225
- to stream PubMed, to step Checkpoint: 002140
- to stream Ncbi, to step Merge: 000467
- to stream Ncbi, to step Curation: 000467
- to stream Ncbi, to step Checkpoint: 000467
- to stream Main, to step Merge: 002D65
- to stream Main, to step Curation: 002D36
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Determinants for prediction of malignant potential by metalloproteinase:E-cadherin ratio in prostate core needle biopsy.</title><author><name sortKey="Ohmori, H" sort="Ohmori, H" uniqKey="Ohmori H" first="H" last="Ohmori">H. Ohmori</name><affiliation wicri:level="1"><nlm:affiliation>Department of Molecular Pathology, Nara Medical University School of Medicine, Kashihara, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Molecular Pathology, Nara Medical University School of Medicine, Kashihara</wicri:regionArea><wicri:noRegion>Kashihara</wicri:noRegion></affiliation></author><author><name sortKey="Fujii, K" sort="Fujii, K" uniqKey="Fujii K" first="K" last="Fujii">K. Fujii</name></author><author><name sortKey="Sasahira, T" sort="Sasahira, T" uniqKey="Sasahira T" first="T" last="Sasahira">T. Sasahira</name></author><author><name sortKey="Ukai, R" sort="Ukai, R" uniqKey="Ukai R" first="R" last="Ukai">R. Ukai</name></author><author><name sortKey="Ikeda, M" sort="Ikeda, M" uniqKey="Ikeda M" first="M" last="Ikeda">M. Ikeda</name></author><author><name sortKey="Kobayashi, K" sort="Kobayashi, K" uniqKey="Kobayashi K" first="K" last="Kobayashi">K. Kobayashi</name></author><author><name sortKey="Maruyama, A" sort="Maruyama, A" uniqKey="Maruyama A" first="A" last="Maruyama">A. Maruyama</name></author><author><name sortKey="Kuniyasu, H" sort="Kuniyasu, H" uniqKey="Kuniyasu H" first="H" last="Kuniyasu">H. Kuniyasu</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:16943690</idno><idno type="pmid">16943690</idno><idno type="doi">10.1159/000094494</idno><idno type="wicri:Area/PubMed/Corpus">002225</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002225</idno><idno type="wicri:Area/PubMed/Curation">002225</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002225</idno><idno type="wicri:Area/PubMed/Checkpoint">002140</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002140</idno><idno type="wicri:Area/Ncbi/Merge">000467</idno><idno type="wicri:Area/Ncbi/Curation">000467</idno><idno type="wicri:Area/Ncbi/Checkpoint">000467</idno><idno type="wicri:doubleKey">1015-2008:2006:Ohmori H:determinants:for:prediction</idno><idno type="wicri:Area/Main/Merge">002D65</idno><idno type="wicri:Area/Main/Curation">002D36</idno><idno type="wicri:Area/Main/Exploration">002D36</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Determinants for prediction of malignant potential by metalloproteinase:E-cadherin ratio in prostate core needle biopsy.</title><author><name sortKey="Ohmori, H" sort="Ohmori, H" uniqKey="Ohmori H" first="H" last="Ohmori">H. Ohmori</name><affiliation wicri:level="1"><nlm:affiliation>Department of Molecular Pathology, Nara Medical University School of Medicine, Kashihara, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Molecular Pathology, Nara Medical University School of Medicine, Kashihara</wicri:regionArea><wicri:noRegion>Kashihara</wicri:noRegion></affiliation></author><author><name sortKey="Fujii, K" sort="Fujii, K" uniqKey="Fujii K" first="K" last="Fujii">K. Fujii</name></author><author><name sortKey="Sasahira, T" sort="Sasahira, T" uniqKey="Sasahira T" first="T" last="Sasahira">T. Sasahira</name></author><author><name sortKey="Ukai, R" sort="Ukai, R" uniqKey="Ukai R" first="R" last="Ukai">R. Ukai</name></author><author><name sortKey="Ikeda, M" sort="Ikeda, M" uniqKey="Ikeda M" first="M" last="Ikeda">M. Ikeda</name></author><author><name sortKey="Kobayashi, K" sort="Kobayashi, K" uniqKey="Kobayashi K" first="K" last="Kobayashi">K. Kobayashi</name></author><author><name sortKey="Maruyama, A" sort="Maruyama, A" uniqKey="Maruyama A" first="A" last="Maruyama">A. Maruyama</name></author><author><name sortKey="Kuniyasu, H" sort="Kuniyasu, H" uniqKey="Kuniyasu H" first="H" last="Kuniyasu">H. Kuniyasu</name></author></analytic><series><title level="j">Pathobiology : journal of immunopathology, molecular and cellular biology</title><idno type="ISSN">1015-2008</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Biomarkers, Tumor (genetics)</term><term>Biomarkers, Tumor (metabolism)</term><term>Biopsy, Needle</term><term>Cadherins (genetics)</term><term>Cadherins (metabolism)</term><term>Disease Progression</term><term>Gene Expression Regulation, Neoplastic</term><term>Humans</term><term>Male</term><term>Matrix Metalloproteinase 2 (genetics)</term><term>Matrix Metalloproteinase 2 (metabolism)</term><term>Matrix Metalloproteinase 9 (genetics)</term><term>Matrix Metalloproteinase 9 (metabolism)</term><term>Neoplasm Staging</term><term>Predictive Value of Tests</term><term>Prognosis</term><term>Prostatic Neoplasms (diagnosis)</term><term>Prostatic Neoplasms (metabolism)</term><term>Prostatic Neoplasms (pathology)</term><term>RNA, Messenger (genetics)</term><term>RNA, Messenger (metabolism)</term><term>Reference Values</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ARN messager (génétique)</term><term>ARN messager (métabolisme)</term><term>Cadhérines (génétique)</term><term>Cadhérines (métabolisme)</term><term>Humains</term><term>Marqueurs biologiques tumoraux (génétique)</term><term>Marqueurs biologiques tumoraux (métabolisme)</term><term>Matrix metalloproteinase 2 (génétique)</term><term>Matrix metalloproteinase 2 (métabolisme)</term><term>Matrix metalloproteinase 9 (génétique)</term><term>Matrix metalloproteinase 9 (métabolisme)</term><term>Mâle</term><term>Ponction-biopsie à l'aiguille</term><term>Pronostic</term><term>Régulation de l'expression des gènes tumoraux</term><term>Stade de la tumeur</term><term>Tumeurs de la prostate (anatomopathologie)</term><term>Tumeurs de la prostate (diagnostic)</term><term>Tumeurs de la prostate (métabolisme)</term><term>Valeur prédictive des tests</term><term>Valeurs de référence</term><term>Évolution de la maladie</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Biomarkers, Tumor</term><term>Cadherins</term><term>Matrix Metalloproteinase 2</term><term>Matrix Metalloproteinase 9</term><term>RNA, Messenger</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Biomarkers, Tumor</term><term>Cadherins</term><term>Matrix Metalloproteinase 2</term><term>Matrix Metalloproteinase 9</term><term>RNA, Messenger</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs de la prostate</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Prostatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Tumeurs de la prostate</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>ARN messager</term><term>Cadhérines</term><term>Marqueurs biologiques tumoraux</term><term>Matrix metalloproteinase 2</term><term>Matrix metalloproteinase 9</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Prostatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>ARN messager</term><term>Cadhérines</term><term>Marqueurs biologiques tumoraux</term><term>Matrix metalloproteinase 2</term><term>Matrix metalloproteinase 9</term><term>Tumeurs de la prostate</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Prostatic Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Biopsy, Needle</term><term>Disease Progression</term><term>Gene Expression Regulation, Neoplastic</term><term>Humans</term><term>Male</term><term>Neoplasm Staging</term><term>Predictive Value of Tests</term><term>Prognosis</term><term>Reference Values</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Mâle</term><term>Ponction-biopsie à l'aiguille</term><term>Pronostic</term><term>Régulation de l'expression des gènes tumoraux</term><term>Stade de la tumeur</term><term>Valeur prédictive des tests</term><term>Valeurs de référence</term><term>Évolution de la maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">According to a good correlation between in situ hybridization-based metalloproteinase-2/9:E-cadherin ratio (MER) and the pathological stage of prostate cancer, we set the cutoff line of MER at 6.0 (MER>6) to distinguish between organ-confined (pT2) and advanced diseases (pT3a-b/N1). In this study, we looked at the factors affecting MER and leading to a misprediction of the pathological stage. We examined MER in 39 paired specimens of prostate core needle biopsy and prostatectomy from the same patient and compared these MERs. In 34 (87%) of 39 cases, the MER of biopsy was correlated with the final pathological stage (pT2 vs. pT3a-b/N1). MER ranges in pT3a-b/N1 cancer were significantly wider than those in pT2 cancer (p < 0.01). The number of MER>6 fields in Gleason score 8-9 cancer was larger than that in Gleason score 7 cancer (p < 0.0001). In 5 cases where there was a failure to distinguish pT2 from pT3a-b/N1, the misdiagnosis was significantly associated with a small number of biopsies (4 or 6 specimens; p = 0.0469), a small amount of tumor tissue in biopsy specimens (less than 5 mm; p = 0.0492), and a wide MER range (more than 5.0; high intratumoral heterogeneity; p = 0.0202). Considering these factors increases the usefulness of preoperative prediction of the final pathological stage by MER in prostate cancer.</div></front></TEI><affiliations><list><country><li>Japon</li></country></list><tree><noCountry><name sortKey="Fujii, K" sort="Fujii, K" uniqKey="Fujii K" first="K" last="Fujii">K. Fujii</name><name sortKey="Ikeda, M" sort="Ikeda, M" uniqKey="Ikeda M" first="M" last="Ikeda">M. Ikeda</name><name sortKey="Kobayashi, K" sort="Kobayashi, K" uniqKey="Kobayashi K" first="K" last="Kobayashi">K. Kobayashi</name><name sortKey="Kuniyasu, H" sort="Kuniyasu, H" uniqKey="Kuniyasu H" first="H" last="Kuniyasu">H. Kuniyasu</name><name sortKey="Maruyama, A" sort="Maruyama, A" uniqKey="Maruyama A" first="A" last="Maruyama">A. Maruyama</name><name sortKey="Sasahira, T" sort="Sasahira, T" uniqKey="Sasahira T" first="T" last="Sasahira">T. Sasahira</name><name sortKey="Ukai, R" sort="Ukai, R" uniqKey="Ukai R" first="R" last="Ukai">R. Ukai</name></noCountry><country name="Japon"><noRegion><name sortKey="Ohmori, H" sort="Ohmori, H" uniqKey="Ohmori H" first="H" last="Ohmori">H. Ohmori</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D36 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002D36 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:16943690
|texte= Determinants for prediction of malignant potential by metalloproteinase:E-cadherin ratio in prostate core needle biopsy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:16943690" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |